Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 7/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30078137 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL30078205 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL30078040 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL30078177 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL30078127 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL30078178 | 1.00 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL30078092 | 0.99 | OPRM1 (0.54) | OPRM1OPRK1NMUR2NMUR1IL23R | |
| SCHEMBL29932071 | 0.97 | NMUR2 (0.56) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| SCHEMBL29932143 | 0.97 | NMUR2 (0.56) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| SCHEMBL30078132 | 0.97 | NMUR2 (0.56) | OPRM1OPRK1NMUR2NMUR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648293-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-16 | — | — | US | disclosed |
| US-11642393-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-09 | — | — | US | disclosed |
| US-11638743-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-11638742-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-20230104343-A1 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | BIOLINERX LTD. (IL) | 2023-04-06 | — | — | US | disclosed |
| US-11612638-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| US-11607444-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-03-21 | — | — | US | disclosed |
| US-11596666-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-03-07 | — | — | US | disclosed |
| US-11590200-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-02-28 | — | — | US | disclosed |
| US-11559562-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2023-01-24 | — | — | US | disclosed |
| US-11554159-B2 | Compositions and methods for treating cancer | Blokine Therapeutics Ltd. (IL) | 2023-01-17 | — | — | US | disclosed |
| US-11534478-B2 | Compositions and methods for treating cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638742-B2 | Compositions and methods for treating cancer | CD274, PDCD1, PDCD1LG2 | OPRM1 727/4885OPRK1 804/4885NMUR2 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.